公开(公告)号：US20160305041A1

公开(公告)日：2016-10-20

申请号：US15034843

申请日：2014-05-28

申请人： (XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMY OF SCIENCES

发明人： Shilie PAN ,  Hui ZHANG ,  Min ZHANG

IPC分类号： C30B29/22 ,  C30B15/14 ,  C30B15/30 ,  C30B15/22 ,  C30B17/00 ,  G02B27/28 ,  C30B19/06 ,  C30B19/08 ,  C30B19/10 ,  C01B35/06 ,  G02B1/08 ,  G02B5/30 ,  C30B15/10 ,  C30B19/02

CPC分类号： C30B29/22 ,  C01B35/066 ,  C30B15/10 ,  C30B15/14 ,  C30B15/22 ,  C30B15/30 ,  C30B17/00 ,  C30B19/02 ,  C30B19/062 ,  C30B19/067 ,  C30B19/08 ,  C30B19/10 ,  C30B29/12 ,  G02B1/08 ,  G02B5/30 ,  G02B27/283

摘要： A preparation method and application of a Na3Ba2(B3O6)2F birefringent crystal, the crystal having a chemical formula of Na3Ba2(B3O6)2F, and belonging to a hexagonal crystal system, the space group being P63/m, and the lattice parameters comprising a=7.3490(6) Å, c=12.6340(2) Å, V=590.93(12) Å3, Z=2; the crystal is used for an infrared/deep ultraviolet waveband, and is an uniaxial negative crystal, ne

摘要翻译： Na3Ba2（B3O6）2F双折射晶体的制备方法和应用，其具有化学式为Na 3 B 2a（B3O 6）2 F的晶体，属于六方晶系，空间群为P63 / m，晶格参数包括 = 7.3490（6）Å，c = 12.6340（2）Å，V = 590.93（12）Å3，Z = 2; 该晶体用于红外/深紫外波段，并且是单轴负晶体，ne

公开(公告)号：US20240140975A1

公开(公告)日：2024-05-02

申请号：US18519408

申请日：2023-11-27

申请人： Shanghai Institute of Materia Medica, Chinese Academyof Sciences ,  Wuhan Institute ofVirology, Chinese Academy of Science ,  Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Science ,  Vigonvita Life Sciences Co., Ltd.

发明人： Yuanchao XIE ,  Gengfu Xiao ,  Yang He ,  Leike Zhang ,  Haji Akber Aisa ,  Hualiang Jiang ,  Jingshan Shen

IPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC分类号： C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

摘要： The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.